Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.4 USD | +5.62% | +19.57% | -29.29% |
Financials (USD)
Sales 2024 * | 307K | Sales 2025 * | 3.1M | Capitalization | 983M |
---|---|---|---|---|---|
Net income 2024 * | -266M | Net income 2025 * | -294M | EV / Sales 2024 * | 1,839 x |
Net cash position 2024 * | 418M | Net cash position 2025 * | 587M | EV / Sales 2025 * | 128 x |
P/E ratio 2024 * |
-3.5
x | P/E ratio 2025 * |
-3.54
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.69% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | +5.62% | ||
1 week | +19.57% | ||
Current month | +16.14% | ||
1 month | -5.29% | ||
3 months | -18.30% | ||
6 months | +1.38% | ||
Current year | -29.29% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 237 M€ | +1.82% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 15.4 | +5.62% | 758,034 |
24-05-02 | 14.58 | +5.58% | 854,629 |
24-05-01 | 13.81 | +4.15% | 1,018,259 |
24-04-30 | 13.26 | -2.50% | 898,245 |
24-04-29 | 13.6 | +5.59% | 1,074,004 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.29% | 983M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- VRDN Stock